Seattle Biotech Lands Investment, Collaboration Deal for Cancer Treatments

Niowave and Aptevo Therapeutics launched a strategic collaboration to support the development of radiopharmaceutical oncology programs.
The collaboration brings together Aptevo’s multispecific immuno-oncology platform technologies and Niowave’s radioisotope production and supply capabilities. The companies expect to advance new treatment options for patients with difficult-to-treat cancers.